American Century Companies Inc. Has $222.99 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

American Century Companies Inc. lifted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 396.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,134,737 shares of the medical research company’s stock after purchasing an additional 905,960 shares during the quarter. American Century Companies Inc. owned 0.63% of IQVIA worth $222,987,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of IQV. GSA Capital Partners LLP acquired a new position in shares of IQVIA in the 3rd quarter valued at $230,000. Empowered Funds LLC boosted its position in shares of IQVIA by 33.9% in the 3rd quarter. Empowered Funds LLC now owns 3,437 shares of the medical research company’s stock valued at $814,000 after purchasing an additional 871 shares during the period. Pathstone Holdings LLC boosted its position in IQVIA by 4.8% during the 3rd quarter. Pathstone Holdings LLC now owns 14,492 shares of the medical research company’s stock worth $3,434,000 after acquiring an additional 667 shares during the period. Caprock Group LLC grew its stake in IQVIA by 11.7% during the 3rd quarter. Caprock Group LLC now owns 3,003 shares of the medical research company’s stock valued at $712,000 after acquiring an additional 315 shares in the last quarter. Finally, Prospera Financial Services Inc acquired a new position in shares of IQVIA in the 3rd quarter valued at about $245,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Up 0.9 %

IQV stock opened at $185.85 on Friday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $254.54. The company has a 50-day moving average of $194.94 and a two-hundred day moving average of $208.45. The stock has a market capitalization of $32.77 billion, a price-to-earnings ratio of 24.78, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Ratings Changes

IQV has been the subject of several research reports. Bank of America decreased their price target on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a report on Friday, December 13th. JPMorgan Chase & Co. dropped their price target on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. Morgan Stanley upped their price target on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Robert W. Baird dropped their price target on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. Finally, Stifel Nicolaus dropped their price target on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.